Report cover image

Global Intratumoral Cancer Therapies Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Publisher GlobalInfoResearch
Published Apr 28, 2025
Length 90 Pages
SKU # GFSH19992014

Description

According to our (Global Info Research) latest study, the global Intratumoral Cancer Therapies market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report is a detailed and comprehensive analysis for global Intratumoral Cancer Therapies market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Intratumoral Cancer Therapies market size and forecasts, in consumption value ($ Million), 2020-2031

Global Intratumoral Cancer Therapies market size and forecasts by region and country, in consumption value ($ Million), 2020-2031

Global Intratumoral Cancer Therapies market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031

Global Intratumoral Cancer Therapies market shares of main players, in revenue ($ Million), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Intratumoral Cancer Therapies

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Intratumoral Cancer Therapies market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb Company, Pfizer, Novarts, Johnson & Johnson, Eli Lilly and Company, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Intratumoral Cancer Therapies market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Lung Cancer
Breast Cancer
Melanoma
Prostate Cancer
Head & Neck Cancer
Others

Market segment by Application
Hospitals
Cancer Research Centres
Clinics

Market segment by players, this report covers
Amgen
AstraZeneca
Bayer
Bristol-Myers Squibb Company
Pfizer
Novarts
Johnson & Johnson
Eli Lilly and Company

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Intratumoral Cancer Therapies product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Intratumoral Cancer Therapies, with revenue, gross margin, and global market share of Intratumoral Cancer Therapies from 2020 to 2025.

Chapter 3, the Intratumoral Cancer Therapies competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Intratumoral Cancer Therapies market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Intratumoral Cancer Therapies.

Chapter 13, to describe Intratumoral Cancer Therapies research findings and conclusion.

Table of Contents

90 Pages
1 Market Overview
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Intratumoral Cancer Therapies by Type
1.3.1 Overview: Global Intratumoral Cancer Therapies Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Intratumoral Cancer Therapies Consumption Value Market Share by Type in 2024
1.3.3 Lung Cancer
1.3.4 Breast Cancer
1.3.5 Melanoma
1.3.6 Prostate Cancer
1.3.7 Head & Neck Cancer
1.3.8 Others
1.4 Global Intratumoral Cancer Therapies Market by Application
1.4.1 Overview: Global Intratumoral Cancer Therapies Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospitals
1.4.3 Cancer Research Centres
1.4.4 Clinics
1.5 Global Intratumoral Cancer Therapies Market Size & Forecast
1.6 Global Intratumoral Cancer Therapies Market Size and Forecast by Region
1.6.1 Global Intratumoral Cancer Therapies Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Intratumoral Cancer Therapies Market Size by Region, (2020-2031)
1.6.3 North America Intratumoral Cancer Therapies Market Size and Prospect (2020-2031)
1.6.4 Europe Intratumoral Cancer Therapies Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Intratumoral Cancer Therapies Market Size and Prospect (2020-2031)
1.6.6 South America Intratumoral Cancer Therapies Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Intratumoral Cancer Therapies Market Size and Prospect (2020-2031)
2 Company Profiles
2.1 Amgen
2.1.1 Amgen Details
2.1.2 Amgen Major Business
2.1.3 Amgen Intratumoral Cancer Therapies Product and Solutions
2.1.4 Amgen Intratumoral Cancer Therapies Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Amgen Recent Developments and Future Plans
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Intratumoral Cancer Therapies Product and Solutions
2.2.4 AstraZeneca Intratumoral Cancer Therapies Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 AstraZeneca Recent Developments and Future Plans
2.3 Bayer
2.3.1 Bayer Details
2.3.2 Bayer Major Business
2.3.3 Bayer Intratumoral Cancer Therapies Product and Solutions
2.3.4 Bayer Intratumoral Cancer Therapies Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Bayer Recent Developments and Future Plans
2.4 Bristol-Myers Squibb Company
2.4.1 Bristol-Myers Squibb Company Details
2.4.2 Bristol-Myers Squibb Company Major Business
2.4.3 Bristol-Myers Squibb Company Intratumoral Cancer Therapies Product and Solutions
2.4.4 Bristol-Myers Squibb Company Intratumoral Cancer Therapies Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer Intratumoral Cancer Therapies Product and Solutions
2.5.4 Pfizer Intratumoral Cancer Therapies Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Pfizer Recent Developments and Future Plans
2.6 Novarts
2.6.1 Novarts Details
2.6.2 Novarts Major Business
2.6.3 Novarts Intratumoral Cancer Therapies Product and Solutions
2.6.4 Novarts Intratumoral Cancer Therapies Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Novarts Recent Developments and Future Plans
2.7 Johnson & Johnson
2.7.1 Johnson & Johnson Details
2.7.2 Johnson & Johnson Major Business
2.7.3 Johnson & Johnson Intratumoral Cancer Therapies Product and Solutions
2.7.4 Johnson & Johnson Intratumoral Cancer Therapies Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Johnson & Johnson Recent Developments and Future Plans
2.8 Eli Lilly and Company
2.8.1 Eli Lilly and Company Details
2.8.2 Eli Lilly and Company Major Business
2.8.3 Eli Lilly and Company Intratumoral Cancer Therapies Product and Solutions
2.8.4 Eli Lilly and Company Intratumoral Cancer Therapies Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Eli Lilly and Company Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Intratumoral Cancer Therapies Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Intratumoral Cancer Therapies by Company Revenue
3.2.2 Top 3 Intratumoral Cancer Therapies Players Market Share in 2024
3.2.3 Top 6 Intratumoral Cancer Therapies Players Market Share in 2024
3.3 Intratumoral Cancer Therapies Market: Overall Company Footprint Analysis
3.3.1 Intratumoral Cancer Therapies Market: Region Footprint
3.3.2 Intratumoral Cancer Therapies Market: Company Product Type Footprint
3.3.3 Intratumoral Cancer Therapies Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Intratumoral Cancer Therapies Consumption Value and Market Share by Type (2020-2025)
4.2 Global Intratumoral Cancer Therapies Market Forecast by Type (2026-2031)
5 Market Size Segment by Application
5.1 Global Intratumoral Cancer Therapies Consumption Value Market Share by Application (2020-2025)
5.2 Global Intratumoral Cancer Therapies Market Forecast by Application (2026-2031)
6 North America
6.1 North America Intratumoral Cancer Therapies Consumption Value by Type (2020-2031)
6.2 North America Intratumoral Cancer Therapies Market Size by Application (2020-2031)
6.3 North America Intratumoral Cancer Therapies Market Size by Country
6.3.1 North America Intratumoral Cancer Therapies Consumption Value by Country (2020-2031)
6.3.2 United States Intratumoral Cancer Therapies Market Size and Forecast (2020-2031)
6.3.3 Canada Intratumoral Cancer Therapies Market Size and Forecast (2020-2031)
6.3.4 Mexico Intratumoral Cancer Therapies Market Size and Forecast (2020-2031)
7 Europe
7.1 Europe Intratumoral Cancer Therapies Consumption Value by Type (2020-2031)
7.2 Europe Intratumoral Cancer Therapies Consumption Value by Application (2020-2031)
7.3 Europe Intratumoral Cancer Therapies Market Size by Country
7.3.1 Europe Intratumoral Cancer Therapies Consumption Value by Country (2020-2031)
7.3.2 Germany Intratumoral Cancer Therapies Market Size and Forecast (2020-2031)
7.3.3 France Intratumoral Cancer Therapies Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Intratumoral Cancer Therapies Market Size and Forecast (2020-2031)
7.3.5 Russia Intratumoral Cancer Therapies Market Size and Forecast (2020-2031)
7.3.6 Italy Intratumoral Cancer Therapies Market Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Intratumoral Cancer Therapies Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Intratumoral Cancer Therapies Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Intratumoral Cancer Therapies Market Size by Region
8.3.1 Asia-Pacific Intratumoral Cancer Therapies Consumption Value by Region (2020-2031)
8.3.2 China Intratumoral Cancer Therapies Market Size and Forecast (2020-2031)
8.3.3 Japan Intratumoral Cancer Therapies Market Size and Forecast (2020-2031)
8.3.4 South Korea Intratumoral Cancer Therapies Market Size and Forecast (2020-2031)
8.3.5 India Intratumoral Cancer Therapies Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Intratumoral Cancer Therapies Market Size and Forecast (2020-2031)
8.3.7 Australia Intratumoral Cancer Therapies Market Size and Forecast (2020-2031)
9 South America
9.1 South America Intratumoral Cancer Therapies Consumption Value by Type (2020-2031)
9.2 South America Intratumoral Cancer Therapies Consumption Value by Application (2020-2031)
9.3 South America Intratumoral Cancer Therapies Market Size by Country
9.3.1 South America Intratumoral Cancer Therapies Consumption Value by Country (2020-2031)
9.3.2 Brazil Intratumoral Cancer Therapies Market Size and Forecast (2020-2031)
9.3.3 Argentina Intratumoral Cancer Therapies Market Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Intratumoral Cancer Therapies Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Intratumoral Cancer Therapies Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Intratumoral Cancer Therapies Market Size by Country
10.3.1 Middle East & Africa Intratumoral Cancer Therapies Consumption Value by Country (2020-2031)
10.3.2 Turkey Intratumoral Cancer Therapies Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Intratumoral Cancer Therapies Market Size and Forecast (2020-2031)
10.3.4 UAE Intratumoral Cancer Therapies Market Size and Forecast (2020-2031)
11 Market Dynamics
11.1 Intratumoral Cancer Therapies Market Drivers
11.2 Intratumoral Cancer Therapies Market Restraints
11.3 Intratumoral Cancer Therapies Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Intratumoral Cancer Therapies Industry Chain
12.2 Intratumoral Cancer Therapies Upstream Analysis
12.3 Intratumoral Cancer Therapies Midstream Analysis
12.4 Intratumoral Cancer Therapies Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.